PD-L1 points to poor outcomes in EGFR lung cancer

High expression of PD-L1 is associated with shorter survival and resistance to targeted therapies in patients with EGFR-mutant lung adenocarcinoma, according to a new study. While PD-L1 expression has been shown to be associated with response to immunotherapy, previous reports have yielded conflicting results on whether it is also predictive for EGFR tyrosine kinase inhibitor ...